Zeng T - Search Results

1

PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.

Wang Z, Zeng T, Li Y, Zhang D, Yuan Z, Huang M, Yang Y, Zhou W. Wang Z, et al. Among authors: zeng t. Front Immunol. 2021 Dec 24;12:799822. doi: 10.3389/fimmu.2021.799822. eCollection 2021. Front Immunol. 2021. PMID: 35003124 Free PMC article. Review.

2

[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].

Lu J, Hou J, Zhang CY, Yuan ZG, Lan HF, Zhou F, Fan JL, Zhou LL, Du J, Jiang H, Jin LN, Zeng TM, Fu WJ. Lu J, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):309-12. doi: 10.3760/cma.j.issn.0253-2727.2013.04.013. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668202 Chinese.

3

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.

Jiang TY, Pan YF, Wan ZH, Lin YK, Zhu B, Yuan ZG, Ma YH, Shi YY, Zeng TM, Dong LW, Tan YX, Wang HY. Jiang TY, et al. Sci Transl Med. 2020 Sep 23;12(562):eaay0152. doi: 10.1126/scitranslmed.aay0152. Sci Transl Med. 2020. PMID: 32967970

4

Prognosis of Advanced Cholangiocarcinoma in the Palliative Care Setting: A Series of 201 Cases.

Zeng T, Tao C, Yang G, Chen X, Yuan Z. Zeng T, et al. Altern Ther Health Med. 2022 Feb;28(2):24-31. Altern Ther Health Med. 2022. PMID: 34653023 Free article.

5

Current and emerging immunotherapeutic approaches for biliary tract cancers.

Yuan ZG, Zeng TM, Tao CJ. Yuan ZG, et al. Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):440-449. doi: 10.1016/j.hbpd.2022.08.015. Epub 2022 Sep 7. Hepatobiliary Pancreat Dis Int. 2022. PMID: 36115807 Review.

6

Zeng TM, Pan YF, Yuan ZG, Chen DS, Song YJ, Gao Y. Zeng TM, et al. Front Immunol. 2022 Sep 9;13:943066. doi: 10.3389/fimmu.2022.943066. eCollection 2022. Front Immunol. 2022. PMID: 36159865 Free PMC article.

7

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.

Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, Han Q, Cheng Z, Shang PP, Dong YL, Xu HM, Guo LP, Chen DS, Song YJ, Qi C, Deng WL, Yuan ZG. Zeng TM, et al. Nat Commun. 2023 Mar 11;14(1):1340. doi: 10.1038/s41467-023-37030-w. Nat Commun. 2023. PMID: 36906670 Free PMC article. Clinical Trial.

8

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK.

Jiang TY, Cui XW, Zeng TM, Pan YF, Lin YK, Feng XF, Tan YX, Yuan ZG, Dong LW, Wang HY. Jiang TY, et al. Sci Transl Med. 2023 Jul 12;15(704):eadd7464. doi: 10.1126/scitranslmed.add7464. Epub 2023 Jul 12. Sci Transl Med. 2023. PMID: 37437018

9

Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor.

Cheng Z, Zeng T, Yang G, Liu D, Zheng Z, Yuan Z. Cheng Z, et al. Among authors: zeng t. Liver Cancer. 2023 Mar 28;12(3):281-288. doi: 10.1159/000530273. eCollection 2023 Aug. Liver Cancer. 2023. PMID: 37593364 Free PMC article.

10

Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.

Zeng TM, Jiang TY, Yang G, Cheng Z, Lou C, Wei W, Tao CJ, Hu S, Wang H, Cui XW, Tan YX, Dong LW, Wang HY, Yuan ZG. Zeng TM, et al. Clin Transl Med. 2024 May;14(5):e1675. doi: 10.1002/ctm2.1675. Clin Transl Med. 2024. PMID: 38689424 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,446 results

Search Page

Filters